More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.37B
EPS
-2.03
P/E ratio
--
Price to sales
3.12
Dividend yield
--
Beta
0.871625
Previous close
$23.54
Today's open
$23.36
Day's range
$23.03 - $24.11
52 week range
$16.67 - $38.11
show more
CEO
Larry Wood
Employees
888
Headquarters
San Jose, CA
Exchange
NASDAQ Global Market
Shares outstanding
57536121
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
PROCEPT BioRobotics Q3 Earnings Call Highlights
PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements at new U.S. accounts.
MarketBeat • Nov 5, 2026

PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.
GlobeNewsWire • Nov 4, 2026

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.
Zacks Investment Research • Nov 5, 2026

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PROCEPT BIOROBO (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

PROCEPT BioRobotics: Compelling Bet On Aquablation's Growth
PROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial potential. That should eventually require replacements and help equipment revenues. In that sense, PRCT's recurring sales with consumables could become increasingly valuable. However, that assumes that procedure growth continues as well.
Seeking Alpha • Oct 23, 2026

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
GlobeNewsWire • Oct 12, 2026

PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation
SAN DIEGO, Oct. 1, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit has been filed concerning certain investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT). Investors who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or +1 (858) 779-1554.
PRNewsWire • Oct 1, 2026

LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation
A lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation shares. NASDAQ: PRCT investors should contact the Shareholders Foundation
GlobeNewsWire • Sep 30, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
GlobeNewsWire • Sep 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell PROCEPT BioRobotics Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.